Thalidomide: 40 years on.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analysis
What was done
This is a narrative historical review outlining the 40-year clinical trajectory of thalidomide from its withdrawal following the 1961 teratogenicity epidemic to its 1998 FDA marketing approval. The review synthesizes findings on its immunosuppressive use in erythema nodosum leprosum and other inflammatory conditions, its adverse effects, its antiangiogenic properties discovered in 1991, and its trial results in malignant conditions such as multiple myeloma.
What was found
The abstract reports no numerical outcome data or effect sizes beyond noting that over 100 cases of congenital malformations occurred in Brazil following unregulated use. Thalidomide was reported to show clinical efficacy in erythema nodosum leprosum, Behçet's syndrome, graft-versus-host disease, aphthous ulceration in HIV-positive patients, and multiple myeloma. Conversely, it was associated with increased mortality in epidermal necrolysis, and the precise mechanism of embryopathic action remained unknown.
Why it matters
The paper contextualizes the therapeutic rehabilitation of a notorious teratogen into an approved therapy for specific dermatological and oncological indications under strict regulation.
Limits
As a narrative review, it lacks a systematic literature search methodology, quality assessment of cited studies, and quantitative data synthesis. Details regarding study designs, sample sizes, comparator groups, and specific treatment regimens are omitted in the abstract.
Cited by
- supports Thalidomide was originally developed as an anti-nausea drug for pregnant women, was removed from the market due to causing severe limb-reduction birth defects, and was later FDA-approved for leprosy and multiple myeloma due to its anti-angiogenic properties.